Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6286 to 6300 of 7707 results

  1. Excessive daytime sleepiness in Parkinson's disease: modafinil (ESUOM48)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Evidence summary
    Published
    29 September 2015

  2. Postural hypotension in adults: midodrine (ESUOM5)

    This evidence summary has been updated and replaced by NICE evidence summary: new medicines 61.

    Evidence summary
    Published
    5 February 2013

  3. Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)

    This evidence summary has been updated and replaced by NICE guideline NG131.

    Evidence summary
    Published
    5 January 2016

  4. Pulmonary hypertension in neonates: sildenafil (ESUOM51)

    This evidence summary has been withdrawn following updated information in the summary of product characteristics on the off-label use of sildenafil (Revatio) in neonates with persistent pulmonary hypertension of the newborn.

    Evidence summary
    Published
    29 March 2016

  5. Systemic lupus erythematosus: oral mycophenolate (ESUOM36)

    This evidence summary has been withdrawn following the MHRA pregnancy-prevention advice issued for women and men taking mycophenolate.

    Evidence summary
    Published
    18 November 2014

  6. Cystic fibrosis: long-term azithromycin (ESUOM37)

    This evidence summary has been updated and replaced by NICE guideline NG78.

    Evidence summary
    Published
    25 November 2014

  7. Non-cystic fibrosis bronchiectasis: long-term azithromycin (ESUOM38)

    This evidence summary has been updated and replaced by NICE guideline NG117.

    Evidence summary
    Published
    25 November 2014

  8. Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine (ESUOM40)

    This evidence summary has been updated and replaced by NICE guideline NG97.

    Evidence summary
    Published
    10 March 2015

  9. Management of aggression, agitation and behavioural disturbances in dementia: valproate preparations (ESUOM41)

    This evidence summary has been updated and replaced by NICE guideline NG97.

    Evidence summary
    Published
    10 March 2015

  10. Interstitial cystitis: oral pentosan polysulfate sodium (ESUOM43)

    This guidance has been updated and replaced by NICE technology appraisal guidance 610.

    Evidence summary
    Published
    21 April 2015

  11. Rapid tranquillisation in mental health settings: promethazine hydrochloride (ESUOM28)

    This evidence summary has been updated and replaced by NICE guideline NG10.

    Evidence summary
    Published
    11 March 2014

  12. Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin (ESUOM2)

    This evidence summary has been withdrawn because licensed products are now available.

    Evidence summary
    Published
    4 January 2013

  13. Transient ischaemic attack: clopidogrel (ESUOM23)

    This evidence summary has been withdrawn and NICE accredited guidance is available from the Royal College of Physicians.

    Evidence summary
    Published
    13 December 2013

  14. Critical limb ischaemia in peripheral vascular disease: intravenous iloprost (ESUOM24)

    April 2019: This evidence summary has been withdrawn because a product containing intravenous iloprost with a marketing authorisation for treating critical limb ischaemia in peripheral vascular disease is now available in the UK.

    Evidence summary
    Published
    17 December 2013

  15. Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)

    This evidence summary has been updated and replaced by NICE guideline NG117.

    Evidence summary
    Published
    6 January 2014